A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.
about
Emerging treatment options for nasopharyngeal carcinomaTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaMetronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Epstein-barr virus vaccines.Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.A review of dendritic cell therapy for cancer: progress and challenges.Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.Investigational drugs for nasopharyngeal carcinoma.Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression.Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion.LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma.EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells.EBV and nasopharyngeal carcinoma: a target for cellular therapies.Trial watch: Dendritic cell-based interventions for cancer therapy.Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.Head and neck cancer in Hong Kong.Current Strategies to Enhance Anti-Tumour Immunity.Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
P2860
Q26995560-84BC3D10-B684-432E-A687-6EC641CFFFBBQ27016002-BE7DE23F-B8B8-439D-9FD4-09A586A0B6A9Q30846827-A3529A2B-97FE-458B-987D-C08FC49EB553Q35053650-F003BEC8-A795-477F-B26F-F6A2C30EC761Q35068768-0037E2F9-5084-4F03-9C06-1525BA712B5CQ35142912-97D8827F-887A-42C5-B447-1539481EB61DQ36241068-7F985CFA-1E9C-4C92-9771-BA33ED36FC2EQ37690437-8AE98E36-439F-4AF8-BE44-962C1B3B7E6CQ38099612-16038E0B-7452-4089-9C8D-F125A35FB327Q38525041-7C198BDF-BBDE-4B27-B75A-ACD3B0D4C045Q38635035-55584AD3-2D97-455A-9D94-CB22C444F8A6Q38690528-5DA97A66-DF41-46F9-BD7A-96061CFD3BCAQ38821356-28FA82C3-0E30-4995-9F06-E027132AD23EQ39024097-868A3287-AF54-41C9-B53F-6309D78FDDEDQ39170011-36947F59-8805-46FF-B82B-1F02AE3A394FQ40041237-D93786AB-5FFF-4A01-9085-99BDA8FE1BACQ40113219-2BEE8B6D-E1A2-4501-ACFD-E94BD1612EA9Q40441016-36D8FFC4-DD4F-4637-9A94-ADA6D5232FC6Q40674036-019FDC13-D040-43C9-B64E-394CF7BECD5DQ42280114-3350CA21-4391-44C7-B35D-DA2BCEE2D78FQ42867339-946DD22E-9C2C-4503-80A7-5912C988B920Q49787173-7B036306-3070-4D38-86DA-3A5DE676E06EQ49960053-40080C4C-117A-4FC2-B595-C21140375C57Q52344613-CC392D54-2DEB-47EC-BD74-670D2A76DB1CQ57176933-573020BF-0B8A-4A5D-9E9D-397BD6B735FF
P2860
A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A phase II study evaluating th ...... atic nasopharyngeal carcinoma.
@ast
A phase II study evaluating th ...... atic nasopharyngeal carcinoma.
@en
type
label
A phase II study evaluating th ...... atic nasopharyngeal carcinoma.
@ast
A phase II study evaluating th ...... atic nasopharyngeal carcinoma.
@en
prefLabel
A phase II study evaluating th ...... atic nasopharyngeal carcinoma.
@ast
A phase II study evaluating th ...... atic nasopharyngeal carcinoma.
@en
P2093
P2860
P356
P1433
P1476
A phase II study evaluating th ...... atic nasopharyngeal carcinoma.
@en
P2093
S Gottschalk
P2860
P304
P356
10.1093/ANNONC/MDR341
P577
2011-08-04T00:00:00Z